- Home
- DSS vs VIRX Comparison
DSS vs VIRX Comparison
Compare DSS & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- VIRX
- Stock Information
- Founded
- DSS 1984
- VIRX 2007
- Country
- DSS United States
- VIRX United States
- Employees
- DSS N/A
- VIRX N/A
- Industry
- DSS Containers/Packaging
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSS Consumer Discretionary
- VIRX Health Care
- Exchange
- DSS Nasdaq
- VIRX Nasdaq
- Market Cap
- DSS 7.3M
- VIRX 6.3M
- IPO Year
- DSS N/A
- VIRX N/A
- Fundamental
- Price
- DSS $0.87
- VIRX $0.23
- Analyst Decision
- DSS
- VIRX Buy
- Analyst Count
- DSS 0
- VIRX 4
- Target Price
- DSS N/A
- VIRX $5.00
- AVG Volume (30 Days)
- DSS 64.7K
- VIRX 4.0M
- Earning Date
- DSS 11-13-2024
- VIRX 11-13-2024
- Dividend Yield
- DSS N/A
- VIRX N/A
- EPS Growth
- DSS N/A
- VIRX N/A
- EPS
- DSS N/A
- VIRX N/A
- Revenue
- DSS $25,019,000.00
- VIRX N/A
- Revenue This Year
- DSS N/A
- VIRX N/A
- Revenue Next Year
- DSS N/A
- VIRX N/A
- P/E Ratio
- DSS N/A
- VIRX N/A
- Revenue Growth
- DSS N/A
- VIRX N/A
- 52 Week Low
- DSS $0.81
- VIRX $0.13
- 52 Week High
- DSS $3.08
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- DSS 38.70
- VIRX 69.27
- Support Level
- DSS $0.81
- VIRX $0.20
- Resistance Level
- DSS $0.97
- VIRX $0.26
- Average True Range (ATR)
- DSS 0.09
- VIRX 0.03
- MACD
- DSS -0.00
- VIRX 0.01
- Stochastic Oscillator
- DSS 15.69
- VIRX 77.25
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.